Subclavian carotid transposition for symptomatic subclavian artery stenosis or occlusion. A comparison with the endovascular procedure.

医学 外科 狭窄 锁骨下动脉 血运重建 围手术期 闭塞 血管成形术 锁骨下盗血综合征 经皮 冲程(发动机) 放射科 心肌梗塞 内科学 机械工程 工程类
作者
Enzo Ballotta,Giuseppe Da Giau,Elvira Abbruzzese,E Mion,Renzo Manara,Claudio Baracchini
出处
期刊:PubMed 卷期号:21 (2): 138-44 被引量:20
链接
标识
摘要

Although subclavian-carotid transposition (SCT), among all extrathoracic revascularization procedures, has emerged as the treatment of choice for symptomatic subclavian artery (SA) stenosis or occlusion, some authors advocate percutaneous transluminal angioplasty with stenting as the optimum primary therapy.to assess safety, efficacy and durability of SCT in the treatment of symptomatic SA stenosis or occlusion.review of a prospectively maintained vascular surgical registry.University vascular surgical service.39 patients requiring surgery for symptomatic stenosis or occlusion of the proximal SA from September 1985 to August 1999.SCT.data were collected prospectively from hospital charts and office medical records to determine demographics, risk factors, presenting clinical manifestation, blood pressure differentials, location of the SA lesion and early postoperative outcome. Long-term follow-up was available in all patients. Patency of the revascularization was determined by physical examination and non-invasive laboratory studies.The perioperative mortality and morbidity rates were 2.5% (1 of 39) and 2.5% (1 of 39), respectively. Immediate relief of symptoms was achieved in 100% of cases. Mean follow-up was 6.8 years. Revascularization neither failed during the follow-up period, nor did patients have recurrent symptoms. The overall survival rates at 1, 3, 5 and 10 years were 100%, 100%, 86% and 68%. Overall late mortality rate was 18.4%: no death was stroke related.SCT is a very safe and effective surgical procedure for the treatment of symptomatic SA atherosclerotic disease, ensuring an excellent long-term patency.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助freak采纳,获得10
刚刚
Kins发布了新的文献求助10
1秒前
LYJ完成签到,获得积分10
1秒前
宋宋不迷糊完成签到 ,获得积分10
1秒前
Privacy发布了新的文献求助10
2秒前
YUAN发布了新的文献求助10
3秒前
科研通AI6.3应助SXW采纳,获得10
3秒前
4秒前
汉堡包应助moon采纳,获得10
4秒前
小卷想读博完成签到,获得积分10
5秒前
希望天下0贩的0应助qaz采纳,获得10
5秒前
orixero应助Rong采纳,获得10
5秒前
7秒前
顺利语芙发布了新的文献求助10
8秒前
王开阔完成签到,获得积分10
8秒前
轻松的博完成签到,获得积分10
9秒前
yy发布了新的文献求助10
9秒前
xiaosi发布了新的文献求助10
10秒前
帆蚌侠完成签到,获得积分10
10秒前
星辰大海应助popcoming采纳,获得30
11秒前
bohn123完成签到 ,获得积分10
11秒前
公司账号2发布了新的文献求助10
12秒前
fafa完成签到,获得积分10
12秒前
12秒前
专注垣完成签到,获得积分10
12秒前
13秒前
freak完成签到,获得积分10
13秒前
13秒前
lin完成签到,获得积分10
14秒前
圆圆滚滚完成签到,获得积分10
14秒前
怕孤独的若云完成签到,获得积分10
15秒前
Oliver完成签到,获得积分10
15秒前
黎云完成签到,获得积分10
16秒前
Xx完成签到,获得积分10
17秒前
liyi发布了新的文献求助30
18秒前
Mic应助ccnss采纳,获得10
18秒前
嗦了蜜发布了新的文献求助10
18秒前
爆米花应助优TT采纳,获得10
18秒前
ttt完成签到,获得积分10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Terrorism and Power in Russia: The Empire of (In)security and the Remaking of Politics 1000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6045414
求助须知:如何正确求助?哪些是违规求助? 7817439
关于积分的说明 16248165
捐赠科研通 5190922
什么是DOI,文献DOI怎么找? 2777823
邀请新用户注册赠送积分活动 1760810
关于科研通互助平台的介绍 1643976